On Tuesday, BioNTech (NASDAQ: BNTX), the maker of the COVID-19 vaccine, said that its cancer drug candidate BNT111 significantly improved the response rate in patients with advanced melanoma during a Phase 2 trial.
The trial met its primary endpoint, with data demonstrating a statistically significant improvement in the overall response rate in patients treated with the mRNA immunotherapy candidate BNT111 in combination with the PD-1 checkpoint inhibitor cemiplimab, compared to historical control in patients with advanced melanoma, BioNTech said.
The biotech company said in March it was shifting its focus towards cancer drug development, as it adjusts to the decline in its COVID-19 vaccine business.
(Source: ReutersReuters)
